Market Overview

Impax Commences Shipment of Oxymorphone Hydrochloride Extended-Release Tablets


Impax Laboratories (NASDAQ: IPXL) today announced
that it is commencing shipment of Oxymorphone Hydrochloride
Extended-Release Tablets, through Global Pharmaceuticals, Impax's
generics division.

In June 2010, Impax reached agreement with Endo Pharmaceuticals and
Penwest Pharmaceuticals (collectively Endo) to settle U.S. patent
litigation with regard to the production and sale of its Oxymorphone
Hydrochloride Extended-Release Tablets approved by the U.S. Food and
Drug Administration (FDA) as therapeutically equivalent to the original
formulation of OPANA® ER. Under the terms of the settlement,
Endo agreed to grant Impax a license to sell Impax's approved product on
January 1, 2013.

As a company whose mission is

See full press release

Posted-In: News Guidance Contracts Management


Related Articles (IPXL)

View Comments and Join the Discussion!

Partner Center